Genmab — Maj 2024
-
Godmorgen
-
Genmabs top og bundlinje bedre end ventet - høje omkostninger bør ej bekymre mener Sydbank https://www.proinvestor.com/investornyt/1154366/genmabs-top-og-bundlinje-bedre-end-ventet-hoje-omkostninger-bor-ej-bekymre-mener-sydbank
-
Genmab forbereder sig på vigtig godkendelse for kræfthåb i USA https://www.proinvestor.com/investornyt/1154365/genmab-forbereder-sig-pa-vigtig-godkendelse-for-kraefthab-i-usa
-
ADS lukkede i omregnet kurs 1926.
-
AMGEN earnings Q1 '24- TEPEZZA
(teprotumumab-trbw) generated $424 million of sales in the first quarter. -that is as expected; they guided 'expect mid single growth % over Q1 23
' and this is ~5% https://www.amgen.com/newsroom/press-releases/2024/05/amgen-reports-first-quarter-2024-financial-results
https://investors.amgen.com/static-files/c94912ba-7169-4c84-98b6-23a286b2f72d -
Så er vi forhåbentlig færdige med at krydse kurs 2000
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind